Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

18th International Meeting of the European Society of Gynaecological Oncology (ESGO) /
Clinical trials, ENGOT and use of bevacizumab against angiogenesis

19th - 22nd Oct 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.11.13
Views: 3506

Prof Christian Marth - Innsbruck Medical University, Austria

Prof Christian Marth talks to ecancer at the 2013 ESGO meeting in Liverpool about the organisation of clinical cancer trials in Europe and the European Network of Gynae-oncological Trial Groups (ENGOT).

Prof Marth also talks about angiogenesis, which is an important component to driving the growth of ovarian cancer and two large randomised clinical trials that have demonstrated an improvement of progresion free survival by the addition of bevacizumab to chemotherapy in front-line therapy. The addition of bevacizumab is recommended for patients with advanced ovarian cancer with poor prognostic factors such as FIGO stage IIIB – IV.


ecancer's filming at ESGO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation